Edit |   |
---|---|
Antigenic Specificity | ACVR2A & ACVR2B, Human (Bimagrumab biosimilar) |
Clone | Bimagrumab |
Host Species | Recombinant |
Reactive Species | human |
Isotype | IgG1 lambda |
Format | purified |
Size | 1mg, 5mg |
Concentration | 1mg/ml |
Applications | FCM, IP, ELISA, Neut, FuncS, IF, ICC, MRI |
Reviews / Ratings | If you have used this antibody, please help fellow researchers by submitting reviews to pAbmAbs and antYbuddY. |
Description | Anti-Human ACVR2A & ACVR2B Recombinant Antibody. Bimagrumab (BYM338) is a human monoclonal antibody developed by Novartis to treat pathological muscle loss and weakness. On August 20, 2013, it was announced that bimagrumab had received a breakthrough therapy designation for sporadic inclusion body myositis (sIBM) by the US Food and Drug Administration. |
Immunogen | n/a |
Other Names | Anti-ACVR2A & ACVR2B Recombinant Antibody, Research Grade Bimagrumab, Anti-Human ACVR2A & ACVR2B Recombinant Antibody, BYM338, Antibody Drug Analogues, Monoclonal Antibody, YR1301, Research Grade Biosimilars, Biosimilar Antibody |
Gene, Accession # | CAS: 1356922-05-8 |
Catalog # | YR1301 |
Price | please inquire |
Order / More Info | ACVR2A & ACVR2B, Human (Bimagrumab biosimilar) Antibody from KMD BIOSCIENCE CO. LTD. |
Product Specific References | n/a |